JP2014507446A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507446A5
JP2014507446A5 JP2013555647A JP2013555647A JP2014507446A5 JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5 JP 2013555647 A JP2013555647 A JP 2013555647A JP 2013555647 A JP2013555647 A JP 2013555647A JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
following
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555647A
Other languages
English (en)
Japanese (ja)
Other versions
JP5635708B2 (ja
JP2014507446A (ja
Filing date
Publication date
Priority claimed from US13/478,361 external-priority patent/US8426450B1/en
Application filed filed Critical
Publication of JP2014507446A publication Critical patent/JP2014507446A/ja
Publication of JP2014507446A5 publication Critical patent/JP2014507446A5/ja
Application granted granted Critical
Publication of JP5635708B2 publication Critical patent/JP5635708B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555647A 2011-11-29 2012-11-28 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン Active JP5635708B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564537P 2011-11-29 2011-11-29
US61/564,537 2011-11-29
US13/478,361 2012-05-23
US13/478,361 US8426450B1 (en) 2011-11-29 2012-05-23 Substituted 4-phenyl pyridines having anti-emetic effect
PCT/US2012/066778 WO2013082102A1 (en) 2011-11-29 2012-11-28 Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014210716A Division JP6023146B2 (ja) 2011-11-29 2014-10-15 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン

Publications (3)

Publication Number Publication Date
JP2014507446A JP2014507446A (ja) 2014-03-27
JP2014507446A5 true JP2014507446A5 (enExample) 2014-06-19
JP5635708B2 JP5635708B2 (ja) 2014-12-03

Family

ID=48094815

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013555647A Active JP5635708B2 (ja) 2011-11-29 2012-11-28 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン
JP2014210716A Active JP6023146B2 (ja) 2011-11-29 2014-10-15 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン
JP2016034427A Active JP6074083B2 (ja) 2011-11-29 2016-02-25 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014210716A Active JP6023146B2 (ja) 2011-11-29 2014-10-15 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン
JP2016034427A Active JP6074083B2 (ja) 2011-11-29 2016-02-25 Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン

Country Status (50)

Country Link
US (7) US8426450B1 (enExample)
EP (1) EP2785706B1 (enExample)
JP (3) JP5635708B2 (enExample)
KR (1) KR101979050B1 (enExample)
CN (6) CN111662330B (enExample)
AP (1) AP2014007729A0 (enExample)
AR (1) AR089019A1 (enExample)
AU (1) AU2012346133B2 (enExample)
BR (1) BR112014012878B1 (enExample)
CA (1) CA2850644C (enExample)
CL (1) CL2014001280A1 (enExample)
CO (1) CO6990728A2 (enExample)
CR (1) CR20140312A (enExample)
CY (2) CY1118416T1 (enExample)
DK (1) DK2785706T3 (enExample)
DO (1) DOP2014000115A (enExample)
EA (1) EA026553B1 (enExample)
EC (1) ECSP14003642A (enExample)
ES (1) ES2603958T3 (enExample)
FI (1) FIC20200022I1 (enExample)
FR (1) FR20C1029I2 (enExample)
GE (1) GEP201706695B (enExample)
GT (1) GT201400102A (enExample)
HR (1) HRP20161708T1 (enExample)
HU (2) HUE032288T2 (enExample)
IL (1) IL232859B (enExample)
IN (1) IN2014CN04907A (enExample)
JO (1) JO3202B1 (enExample)
LT (2) LT2785706T (enExample)
MA (1) MA35836B1 (enExample)
MD (1) MD4539C1 (enExample)
ME (1) ME02561B (enExample)
MX (1) MX2014006423A (enExample)
MY (1) MY165514A (enExample)
NI (1) NI201400043A (enExample)
NL (1) NL301047I2 (enExample)
PE (1) PE20141421A1 (enExample)
PH (1) PH12014501199B1 (enExample)
PL (1) PL2785706T3 (enExample)
PT (1) PT2785706T (enExample)
RS (1) RS55448B1 (enExample)
SG (1) SG11201402044XA (enExample)
SI (1) SI2785706T1 (enExample)
SM (2) SMT201600467T1 (enExample)
TN (1) TN2014000165A1 (enExample)
TW (1) TWI638806B (enExample)
UA (1) UA115136C2 (enExample)
UY (1) UY34472A (enExample)
WO (1) WO2013082102A1 (enExample)
ZA (1) ZA201404787B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
EP2648931B1 (en) 2010-12-07 2017-02-01 Allison Transmission, Inc. Energy storage system for hybrid electric vehicle
MX354015B (es) 2011-06-22 2018-02-08 Shionogi & Co Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos.
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US10100030B2 (en) 2013-11-08 2018-10-16 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
IL313498A (en) 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en) 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2017276588B2 (en) * 2016-06-06 2022-06-02 Helsinn Healthcare Sa Physiologically balanced injectable formulations of fosnetupitant
JP7061115B2 (ja) 2016-09-30 2022-04-27 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子の調節因子、医薬組成物、処置の方法、及び当該調節因子を作製するためのプロセス
RS61150B1 (sr) 2016-12-09 2020-12-31 Vertex Pharma Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutske kompozicije, postupci lečenja, i postupak za dobijanje modulatora
CN108619525B (zh) * 2017-03-15 2020-12-29 和龙 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112019028034A2 (pt) 2017-06-30 2020-07-07 Chase Therapeutics Corporation composições de antagonista de nk-1 e métodos para uso no tratamento da depressão
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CN107698500A (zh) * 2017-10-17 2018-02-16 扬子江药业集团四川海蓉药业有限公司 一种奈妥匹坦的制备方法
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
SI3737378T1 (sl) * 2018-01-12 2023-06-30 Orion Corporation Kapljice palonosetrona za oči za zdravljenje ali preprečevanje slabosti in bruhanja
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
CN112778370B (zh) * 2019-11-06 2025-09-26 扬子江药业集团江苏海慈生物药业有限公司 一种制备福奈妥匹坦的方法
WO2021198255A1 (en) 2020-04-03 2021-10-07 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
WO2025036703A1 (en) 2023-08-13 2025-02-20 Helsinn Healthcare Sa Fosnetupitant for administration via intravenous bolus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033846A2 (en) 1997-12-31 1999-07-08 The University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
ES2359235T3 (es) * 1999-02-24 2011-05-19 F. Hoffmann-La Roche Ag Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1.
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
ME01311B (me) * 2000-07-14 2013-12-20 Hoffmann La Roche N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
MXPA03005169A (es) 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP4768010B2 (ja) * 2005-03-23 2011-09-07 エフ．ホフマン−ラ ロシュ アーゲー 嘔吐のためのｎｋ−１アンタゴニストの代謝物
CN101282979B (zh) * 2005-09-13 2011-09-21 卫材R&D管理有限公司 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
MX2012005347A (es) * 2009-11-18 2012-08-03 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados.
ES2647361T3 (es) * 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
PL2646035T3 (pl) * 2010-12-02 2016-08-31 Univ Kansas Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
BR112014029161A2 (pt) 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor

Similar Documents

Publication Publication Date Title
JP2014507446A5 (enExample)
JP2013014622A5 (enExample)
JP2012107057A5 (enExample)
JP2017509667A5 (enExample)
JP2009545527A5 (enExample)
JP2016518337A5 (enExample)
JP2015078230A5 (enExample)
JP2014221779A5 (enExample)
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
JP2012255026A5 (enExample)
JP2013525444A5 (enExample)
JP2013532687A5 (enExample)
JP2018521020A5 (enExample)
JP2012126725A5 (enExample)
JP2013509429A5 (enExample)
JP2015501783A5 (enExample)
JP2014515013A5 (enExample)
JP2011105738A5 (enExample)
JP2015528502A5 (enExample)
JP2017537066A5 (enExample)
JP2013522326A5 (enExample)
EP2833721A4 (en) NICKEL OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
JP2013519675A5 (enExample)
JP2014530840A5 (enExample)